Trial · NCT02667236

A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.

NCT02667236, Phase 3, Completed, Aclaris Therapeutics, Inc.; results first posted 2017-11-13

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis. Trials, record NCT02667236. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02667236

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.
NCT number: NCT02667236
Status: Completed
Phases: Phase 3
Enrollment: 450 participants, actual
Lead sponsor: Aclaris Therapeutics, Inc.
Conditions: Seborrheic Keratosis
Interventions: A-101 Solution, Vehicle Solution
First posted: 2016-01-28
Last updated: 2018-02-06
Results first posted: 2017-11-13

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Proportion of Subjects With Target Lesion Clearance as Assessed by the Physician Lesion Assessment	Day 106 of the study	Proportion of subjects for whom all target lesions were judged to be clear on the Physician Lesion Assessment Scale (PLA=0) at Visit 8. The PLA Scale is a 4 point scale used by the investigator to assess each subject's target SK Lesion.
Secondary	Proportion of Subjects With 3 of 4 Target Lesion Clearance	Day 106 of the study	Proportion of Subjects for whom at least 3 of 4 target lesions were judged to be clear on the Physician Lesion Assessment (PLA=0) at Visit 8

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Proportion of Subjects With Target Lesion Clearance as Assessed by the Physician Lesion Assessment	Day 106 of the study	ITT Population; all randomized subjects	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Proportion of Subjects With 3 of 4 Target Lesion Clearance	Day 106 of the study	ITT population; all randomized subjects	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Proportion of Subjects With Target Lesion Clearance as Assessed by the Physician Lesion Assessment	A-101 Solution	9	Participants
Proportion of Subjects With Target Lesion Clearance as Assessed by the Physician Lesion Assessment	Vehicle Solution	0	Participants
Proportion of Subjects With 3 of 4 Target Lesion Clearance	A-101 Solution	30	Participants
Proportion of Subjects With 3 of 4 Target Lesion Clearance	Vehicle Solution	0	Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	A-101 Solution	223
Overall Study	STARTED	Vehicle Solution	227
Overall Study	COMPLETED	A-101 Solution	220
Overall Study	COMPLETED	Vehicle Solution	226
Overall Study	NOT COMPLETED	A-101 Solution	3
Overall Study	NOT COMPLETED	Vehicle Solution	1

Source ClinicalTrials.gov

Adverse events30

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Nasopharyngitis	Infections and infestations	A-101 Solution	3	223	3
other	Nasopharyngitis	Infections and infestations	Vehicle Solution	7	227	7
other	Bronchitis	Infections and infestations	A-101 Solution	3	223	3
other	Bronchitis	Infections and infestations	Vehicle Solution	1	227	1
other	Upper Respiratory Infection	Infections and infestations	A-101 Solution	1	223	1
other	Upper Respiratory Infection	Infections and infestations	Vehicle Solution	3	227	3
other	Actinic Keratosis	Skin and subcutaneous tissue disorders	A-101 Solution	3	223	3
other	Actinic Keratosis	Skin and subcutaneous tissue disorders	Vehicle Solution	0	227	0
other	Seasonal Allergy	Immune system disorders	A-101 Solution	0	223	0
other	Seasonal Allergy	Immune system disorders	Vehicle Solution	4	227	4

1 to 10 of 30Source ClinicalTrials.gov

See all 30 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	A-101 Solution	0	223
Total, all-cause mortality	Vehicle Solution	0	227
Total, other adverse events	A-101 Solution	10	223
Total, other adverse events	Vehicle Solution	14	227
Total, serious adverse events	A-101 Solution	4	223
Total, serious adverse events	Vehicle Solution	6	227

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
30365590	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons4

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
A-101 Solution vs Vehicle Solution: Proportion of Subjects With 3 of 4 Target Lesion Clearance	Trial comparisons
A-101 Solution vs Vehicle Solution: deaths from any cause	Trial comparisons
A-101 Solution vs Vehicle Solution: Proportion of Subjects With Target Lesion Clearance as Assessed by the Physician Lesion Assessment	Trial comparisons
A-101 Solution vs Vehicle Solution: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02667236

GET https://conductscience.org/api/trials/v1/NCT02667236/events?page=2

API reference For AI assistants